Search the Newsreel

BofA Securities Maintains Aardvark Therapeutics(AARD.US) With Sell Rating

BofA Securities has reiterated its Sell rating on Aardvark Therapeutics (AARD.US). The article does not provide further details regarding the financial implications or the analyst's rationale for maintaining this rating.

Corcept therapeutics chief development officer sells $1.8m in stock

William Guyer, Chief Development Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), sold shares worth approximately $1.85 million on August 10, 2026, through two separate transactions under a 10b5-1 plan. Despite the sales, which occurred while the stock was near its 52-week high, Guyer also acquired …

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?

Diluted earnings per share (diluted EPS) of Spero Therapeutics, Inc. – BMV:SPRO

Hershey Unwraps Biggest Halloween Lineup Yet As Spooky Season Starts Early

Hershey has announced its largest and most diverse Halloween lineup for 2026, launching it early due to increasing consumer demand for "Summerween" and early spooky season celebrations. The expanded portfolio includes returning favorites like Hershey's Cookies 'N' Creme Fangs, new Kit Kat and Reese's …

Relmada (RLMD) Q2 2026 Earnings Call Transcript

BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20

BMO Capital has initiated coverage on MapLight Therapeutics (MPLT.US) with a Buy rating and set a price target of $20. This indicates a positive outlook from the investment firm regarding the company's future stock performance.

Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock

Mittie Doyle, CMO at Avalo Therapeutics (NASDAQ:AVTX), sold 679 shares for $13,580 after exercising stock options under a Rule 10b5-1 trading plan. Following these transactions, she directly holds 51,776 shares and 114,413 stock options. This news follows Avalo's inclusion in the Russell 2000 and …

NTLA|Intellia Therapeutics Inc|Price:11.910|Chg%:+0.080

PTC Therapeutics Is Maintained at Overweight by Barclays

Barclays has reiterated its 'Overweight' rating on PTC Therapeutics (PTCT). The analyst firm maintained a price target of $70.00 for the company's stock. This indicates a positive outlook from Barclays regarding PTC Therapeutics' future performance.

Archer Aviation Shares Drop 5% After Boeing Agreement Puts $1 Billion Challenge Ahead

Why is Hims & Hers Health stock gaining today?

Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus

HLS Therapeutics Inc. (TSE:HLS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Is Herbalife’s Mixed Q2 Results and CFO Exit Altering The Investment Case For Herbalife (HLF)?

Outlook Therapeutics (OTLK) CFO Lawrence Kenyon buys 101K shares plus 101K warrants

Outlook Therapeutics' CFO, Lawrence A. Kenyon, purchased 101,010 shares of common stock and 101,010 accompanying warrants in an underwritten public offering on August 14, 2026. The combined offering price was $0.99 per share and warrant, with the warrants immediately exercisable at $1.10 and expiring …

Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity

Theravance Biopharma Deal Faces Investor Probe

Halper Sadeh LLC is investigating the proposed acquisition of Theravance Biopharma (NASDAQ: TBPH) by Zymeworks Inc. for $17 per share in cash plus a contingent value right. The investigation aims to determine if Theravance shareholders are receiving a fair price and if the company's …

XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock

Edgewise Therapeutics CEO Kevin Koch sold $785,042 worth of company stock on August 12, 2026, primarily to cover tax obligations related to Restricted Stock Unit vesting. Despite the sales, Mr. Koch also acquired new shares through vesting and was granted additional RSUs and stock …

Walleye Capital LLC Takes $1.59 Million Position in PTC Therapeutics, Inc. $PTCT

Walleye Capital LLC has acquired a new position in PTC Therapeutics, Inc., purchasing 19,522 shares valued at approximately $1.59 million during the second quarter. Several other institutional investors also increased their holdings in the biopharmaceutical company, which has an average analyst rating of "Moderate …

Weekly Recap: Sherwin-Williams & Valspar Paint Top This Week’s Stories

This article provides a weekly recap of the most-viewed news stories on Coatings World, highlighting key developments in the paint and coatings industry for the week ending August 15, 2026. Top stories include Sherwin-Williams' new ControlTech systems, Valspar Paint's Ready-Mix collection, and an interview …

LENZ Therapeutics (NASDAQ:LENZ) Stock Rating Upgraded by Zacks Research

Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX

Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST

Walleye Capital LLC has acquired a new stake of 282,568 shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST), valued at approximately $1.18 million. Institutional investors collectively hold 32.45% of the company's stock, while insider ownership stands at 6.81%. Despite a wider-than-expected quarterly loss, analysts maintain a …

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. The investigation focuses on whether Theravance's board failed to secure the best possible price, conducted a fair sales process, …

Plan Group Financial LLC Invests $3.59 Million in Southern Company (The) $SO

Plan Group Financial LLC recently invested $3.59 million in Southern Company, acquiring 37,485 shares. Other institutional investors also adjusted their holdings, with a total of 64.1% of the stock owned by hedge funds and institutions. Southern Company reported better-than-expected EPS but slightly missed revenue …

Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Zacks Research to "Strong Sell"

Zacks Research downgraded Mineralys Therapeutics (NASDAQ:MLYS) to a "Strong Sell" rating, despite a mixed analyst sentiment with an average "Hold" rating and a $49.33 price target. The downgrade follows a significant earnings miss, with the company reporting a quarterly loss of $2.85 per share …

Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold

Zacks Research downgraded Monopar Therapeutics (NASDAQ:MNPR) from a "strong-buy" to a "hold" rating, despite the broader analyst consensus remaining a "moderate buy" with an average price target of $117.42. The company's shares opened at $113.04, trading near their 12-month high, and it recently reported …

Electrotherm Publishes Q1 FY27 Unaudited Results in Financial Express

Walleye Capital LLC Purchases Shares of 102,163 Rapport Therapeutics, Inc. $RAPP

Walleye Capital LLC has acquired a new position in Rapport Therapeutics, purchasing 102,163 shares valued at $4.26 million, representing 0.21% of the company. Despite the stock opening near its 52-week high, Rapport Therapeutics reported a quarterly loss of $1.19 per share, missing estimates. Analysts …

Walleye Capital LLC Acquires Shares of 179,992 Southern First Bancshares, Inc. $SFST

Walleye Capital LLC has acquired 179,992 shares of Southern First Bancshares, Inc. (NASDAQ:SFST) in the second quarter, valued at approximately $11.0 million, representing about 1.9% of the company. Institutional investors now collectively own 75% of SFST. Analysts maintain a positive outlook with a consensus …

128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC

Walleye Capital LLC has acquired 128,006 shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the second quarter, a position valued at approximately $3.82 million. Despite this acquisition and a consensus "Buy" rating from analysts with an average price target of $66, the company reported a …

Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO

Walleye Capital LLC has invested $6.80 million in Allogene Therapeutics, acquiring 3.27 million shares, representing approximately 0.95% of the company. Other institutional investors have also adjusted their stakes, with a significant 83.63% of the stock owned by institutional investors and hedge funds. Allogene Therapeutics …

Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI

Walleye Capital LLC has acquired a new stake of 241,987 shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the second quarter, valued at approximately $4.5 million. This investment contributes to the 95.76% institutional ownership of the company. Trevi Therapeutics maintains a "Buy" consensus rating from …

Oppenheimer Asset Management Inc. Invests $7.82 Million in Southern Copper Corporation $SCCO

Oppenheimer Asset Management Inc. has invested $7.82 million in Southern Copper Corporation (SCCO) by purchasing 44,885 shares. Other institutional investors have also recently adjusted their holdings in the company. Southern Copper reported strong quarterly earnings, beating estimates, and increased its quarterly dividend, though analysts …